Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 34

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 34
---
 based on TELI’s pre-clinical data may prove inaccurate. Frequently, pharmaceutical and biotechnology companies have suffered significant setbacks in clinical trials after achieving positive results in pre-clinical testing and early phase clinical trials, and TELI cannot be certain that TELI will not face similar setbacks. These setbacks may be caused by the fact that pre-clinical and clinical data can be susceptible to varying interpretations and analyses. Furthermore, certain product candidates may perform satisfactorily in pre-clinical studies and clinical trials but nonetheless fail to obtain FDA approval or appropriate approvals by the appropriate regulatory authorities in other countries. If TELI fails to produce positive results in TELI’s clinical trials for TELI’s product candidates, the development timeline and regulatory approval and commercialization prospects for them and as a result TELI’s business and financial prospects would be materially adversely affected.

We have limited marketing experience, and TELI does not anticipate at this time establishing a sales force or distribution and reimbursement capabilities, and TELI may not be able to successfully commercialize any of TELI’s product candidates if they are approved in the future.

If regulatory approval of TELI’s products is ever obtained, TELI’s ability to generate revenues ultimately depends on TELI’s ability to sell TELI’s approved products and secure adequate third-party reimbursement. TELI currently has limited experience in marketing and selling TELI’s products. TELI currently does not have any products approved for sale in the United States or in any other country.

The commercial success of TELI’s product candidates will not even be possible for the foreseeable future and will depend on a number of factors beyond TELI’s control, including the willingness of physicians to prescribe TELI’s products to patients, payers’ willingness and ability to pay for the drugs, the level of pricing achieved, patients’ response to TELI’s drugs and the ability of TELI’s marketing partners to generate sales. There can be no guarantee that TELI will be able to establish or maintain the personnel, systems, arrangements and capabilities necessary to successfully commercialize TELI’s product candidates that may be approved by the FDA in the future. If TELI fails to establish or maintain successful marketing, sales and reimbursement capabilities or fail to enter into successful marketing arrangements with third parties, TELI’s product revenues may suffer.

| 18 |

Should TELI later determine that it is in TELI’s best interest to develop a